Amyloid-β Immunotherapy in Alzheimer's Disease: Challenges and Opportunities. (PubMed, Annu Rev Pathol) - Oct 17, 2026 - "We then compare second-generation agents (i.e., aducanumab, lecanemab, and donanemab) highlighting amyloid-β species selectivity, plaque clearance kinetics, and durability, and we discuss emerging delivery innovations. Finally, we focus on biomarker-guided implementation: blood-based prescreening, confirmation pathways, monitoring of biological response, and treat-to-clear or stopping concepts, alongside unresolved issues of health-system readiness, equity, and budget impact. Registry-enabled learning is emphasized to generate real-world safety and effectiveness evidence."
IO biomarker • Journal • Review • Alzheimer's Disease • CNS Disorders • APOE
|
|
Kenichiro Sato; Saki Nakashima; Takeshi Iwatsubo; Yoshiki Niimi
|